These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 19830741)

  • 1. HIV gag protein is efficiently cross-presented when targeted with an antibody towards the DEC-205 receptor in Flt3 ligand-mobilized murine DC.
    Bozzacco L; Trumpfheller C; Huang Y; Longhi MP; Shimeliovich I; Schauer JD; Park CG; Steinman RM
    Eur J Immunol; 2010 Jan; 40(1):36-46. PubMed ID: 19830741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of the priming efficacy of DNA vaccines encoding dendritic cell-targeted antigens by synergistic toll-like receptor ligands.
    Grossmann C; Tenbusch M; Nchinda G; Temchura V; Nabi G; Stone GW; Kornbluth RS; Uberla K
    BMC Immunol; 2009 Aug; 10():43. PubMed ID: 19650904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8+ T cells in a spectrum of human MHC I haplotypes.
    Bozzacco L; Trumpfheller C; Siegal FP; Mehandru S; Markowitz M; Carrington M; Nussenzweig MC; Piperno AG; Steinman RM
    Proc Natl Acad Sci U S A; 2007 Jan; 104(4):1289-94. PubMed ID: 17229838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A.
    Idoyaga J; Lubkin A; Fiorese C; Lahoud MH; Caminschi I; Huang Y; Rodriguez A; Clausen BE; Park CG; Trumpfheller C; Steinman RM
    Proc Natl Acad Sci U S A; 2011 Feb; 108(6):2384-9. PubMed ID: 21262813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance.
    Bonifaz L; Bonnyay D; Mahnke K; Rivera M; Nussenzweig MC; Steinman RM
    J Exp Med; 2002 Dec; 196(12):1627-38. PubMed ID: 12486105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo.
    Volckmar J; Knop L; Hirsch T; Frentzel S; Erck C; van Ham M; Stegemann-Koniszewski S; Bruder D
    J Vis Exp; 2021 Feb; (168):. PubMed ID: 33616089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8(+) T cell response: a comparative study.
    Cruz LJ; Rosalia RA; Kleinovink JW; Rueda F; Löwik CW; Ossendorp F
    J Control Release; 2014 Oct; 192():209-18. PubMed ID: 25068703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensified and protective CD4+ T cell immunity in mice with anti-dendritic cell HIV gag fusion antibody vaccine.
    Trumpfheller C; Finke JS; López CB; Moran TM; Moltedo B; Soares H; Huang Y; Schlesinger SJ; Park CG; Nussenzweig MC; Granelli-Piperno A; Steinman RM
    J Exp Med; 2006 Mar; 203(3):607-17. PubMed ID: 16505141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FLT3-ligand treatment of humanized mice results in the generation of large numbers of CD141+ and CD1c+ dendritic cells in vivo.
    Ding Y; Wilkinson A; Idris A; Fancke B; O'Keeffe M; Khalil D; Ju X; Lahoud MH; Caminschi I; Shortman K; Rodwell R; Vuckovic S; Radford KJ
    J Immunol; 2014 Feb; 192(4):1982-9. PubMed ID: 24453245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The human cancer antigen mesothelin is more efficiently presented to the mouse immune system when targeted to the DEC-205/CD205 receptor on dendritic cells.
    Wang B; Kuroiwa JM; He LZ; Charalambous A; Keler T; Steinman RM
    Ann N Y Acad Sci; 2009 Sep; 1174():6-17. PubMed ID: 19769731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved cellular and humoral immune responses in vivo following targeting of HIV Gag to dendritic cells within human anti-human DEC205 monoclonal antibody.
    Cheong C; Choi JH; Vitale L; He LZ; Trumpfheller C; Bozzacco L; Do Y; Nchinda G; Park SH; Dandamudi DB; Shrestha E; Pack M; Lee HW; Keler T; Steinman RM; Park CG
    Blood; 2010 Nov; 116(19):3828-38. PubMed ID: 20668230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificity.
    Tsuji T; Matsuzaki J; Kelly MP; Ramakrishna V; Vitale L; He LZ; Keler T; Odunsi K; Old LJ; Ritter G; Gnjatic S
    J Immunol; 2011 Jan; 186(2):1218-27. PubMed ID: 21149605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting of DEC-205 on human dendritic cells results in efficient MHC class II-restricted antigen presentation.
    Birkholz K; Schwenkert M; Kellner C; Gross S; Fey G; Schuler-Thurner B; Schuler G; Schaft N; Dörrie J
    Blood; 2010 Sep; 116(13):2277-85. PubMed ID: 20566893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR.
    Klechevsky E; Flamar AL; Cao Y; Blanck JP; Liu M; O'Bar A; Agouna-Deciat O; Klucar P; Thompson-Snipes L; Zurawski S; Reiter Y; Palucka AK; Zurawski G; Banchereau J
    Blood; 2010 Sep; 116(10):1685-97. PubMed ID: 20530286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo targeting of protein antigens to dendritic cells using anti-DEC-205 single chain antibody improves HIV Gag specific CD4
    Ngu LN; Nji NN; Ambada GE; Sagnia B; Sake CN; Tchadji JC; Njambe Priso GD; Lissom A; Tchouangueu TF; Manga Tebit D; Waffo AB; Park CG; Steinman RM; Überla K; Nchinda GW
    Immun Inflamm Dis; 2019 Jun; 7(2):55-67. PubMed ID: 28474788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination.
    Bonifaz LC; Bonnyay DP; Charalambous A; Darguste DI; Fujii S; Soares H; Brimnes MK; Moltedo B; Moran TM; Steinman RM
    J Exp Med; 2004 Mar; 199(6):815-24. PubMed ID: 15024047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation.
    Singh SK; Stephani J; Schaefer M; Kalay H; García-Vallejo JJ; den Haan J; Saeland E; Sparwasser T; van Kooyk Y
    Mol Immunol; 2009 Dec; 47(2-3):164-74. PubMed ID: 19818504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity.
    Trumpfheller C; Longhi MP; Caskey M; Idoyaga J; Bozzacco L; Keler T; Schlesinger SJ; Steinman RM
    J Intern Med; 2012 Feb; 271(2):183-92. PubMed ID: 22126373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DEC-205-mediated antigen targeting to steady-state dendritic cells induces deletion of diabetogenic CD8⁺ T cells independently of PD-1 and PD-L1.
    Mukherjee G; Geliebter A; Babad J; Santamaria P; Serreze DV; Freeman GJ; Tarbell KV; Sharpe A; DiLorenzo TP
    Int Immunol; 2013 Nov; 25(11):651-60. PubMed ID: 24021877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting dendritic cells in humanized mice receiving adoptive T cells via monoclonal antibodies fused to Flu epitopes.
    Graham JP; Authie P; Yu CI; Zurawski SM; Li XH; Marches F; Flamar AL; Acharya A; Banchereau J; Palucka AK
    Vaccine; 2016 Sep; 34(41):4857-4865. PubMed ID: 27595442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.